# Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors

> **NCT06825455** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Peking University** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Ovarian Cancers
- Peritoneal (metastatic) Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** B7H3 CAR-γδT cells

## Key facts

- **NCT ID:** NCT06825455
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825455, "Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06825455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*